PAMAM-G4 protect the N-(2-hydroxyphenyl)-2-propylpentanamide (HO-AAVPA) and maintain its antiproliferative effects on MCF-7

[1]  J. Correa-Basurto,et al.  Computational study of DMPC liposomes loaded with the N-(2-Hydroxyphenyl)-2-propylpentanamide (HO-AAVPA) and determination of its antiproliferative activity in vitro in NIH-3T3 cells , 2021, Journal of biomolecular structure & dynamics.

[2]  J. Correa-Basurto,et al.  Chemical characterization (LC–MS–ESI), cytotoxic activity and intracellular localization of PAMAM G4 in leukemia cells , 2021, Scientific Reports.

[3]  G. Chamorro-Cevallos,et al.  Anti-epileptic activity, toxicity and teratogenicity in CD1 mice of a novel valproic acid arylamide derivative, N-(2-hydroxyphenyl)-2-propylpentanamide. , 2020, Toxicology and applied pharmacology.

[4]  A. Vaziri,et al.  Breast Tumor Targeting with PAMAM-PEG-5FU-99mTc As a New Therapeutic Nanocomplex: In In-vitro and In-vivo studies , 2020, Biomedical Microdevices.

[5]  J. Correa-Basurto,et al.  Targeting Breast Cancer Cells with G4 PAMAM Dendrimers and Valproic Acid Derivative Complexes. , 2020, Anti-cancer agents in medicinal chemistry.

[6]  M. Rosales-Hernández,et al.  Exploring the biotransformation of N‐(2‐hydroxyphenyl)‐2‐propylpentanamide (an aryl valproic acid derivative) by CYP2C11, using in silico predictions and in vitro studies , 2020, The Journal of pharmacy and pharmacology.

[7]  B. Salih,et al.  Poly(amidoamine) dendrimer-coated magnetic nanoparticles for the fast purification and selective enrichment of glycopeptides and glycans. , 2019, Journal of separation science.

[8]  M. Rashid,et al.  Valproic acid and Stevens‐Johnson syndrome: a systematic review of descriptive studies , 2019, International journal of dermatology.

[9]  M. Gürbüz,et al.  Tren‐Cored PAMAM Dendrimer/Silver Nanocomposites: Efficient Colorimetric Sensors for the Determination of Mercury Ions from Aqueous Solutions , 2019, ChemistrySelect.

[10]  M. Rosales-Hernández,et al.  Pharmacokinetics and tissue distribution of N‐(2‐hydroxyphenyl)‐2‐propylpentanamide in Wistar Rats and its binding properties to human serum albumin , 2019, Journal of pharmaceutical and biomedical analysis.

[11]  M. Rosales-Hernández,et al.  Controlled release of N-(2-hydroxyphenyl)-2-propylpentanamide nanoencapsulated in polymeric micelles of P123 and F127 tested as anti-proliferative agents in MDA-MB-231 cells , 2018, Journal of Drug Delivery Science and Technology.

[12]  M. Rosales-Hernández,et al.  N-(2′-Hydroxyphenyl)-2-propylpentanamide (OH-VPA), a histone deacetylase inhibitor, induces the release of nuclear HMGB1 and modifies ROS levels in HeLa cells , 2018, Oncotarget.

[13]  Michael R Hamblin,et al.  PAMAM dendrimers as efficient drug and gene delivery nanosystems for cancer therapy. , 2018, Applied materials today.

[14]  H. Swai,et al.  Polyamidoamine Dendrimers for Enhanced Solubility of Small Molecules and Other Desirable Properties for Site Specific Delivery: Insights from Experimental and Computational Studies , 2018, Molecules.

[15]  P. Garg,et al.  Characterization of forced degradation products of canagliflozine by liquid chromatography/quadrupole time-of-flight tandem mass spectrometry and in silico toxicity predictions. , 2018, Rapid communications in mass spectrometry : RCM.

[16]  J. Correa-Basurto,et al.  Binding free energy calculations using MMPB/GBSA approaches for PAMAM-G4-drug complexes at neutral, basic and acid pH conditions. , 2017, Journal of molecular graphics & modelling.

[17]  M. Gürbüz,et al.  Synthesis of surface-modified TREN-cored PAMAM dendrimers and their effects on the solubility of sulfamethoxazole (SMZ) as an analog antibiotic drug , 2017, Pharmaceutical development and technology.

[18]  R. Addeo,et al.  Epigenetic control of gene expression: Potential implications for cancer treatment. , 2017, Critical reviews in oncology/hematology.

[19]  V. Awasthi,et al.  Stability study on an anti-cancer drug 4-(3,5-bis(2-chlorobenzylidene)-4-oxo-piperidine-1-yl)-4-oxo-2-butenoic acid (CLEFMA) using a stability-indicating HPLC method , 2016, Journal of pharmaceutical analysis.

[20]  M. Qiao,et al.  The cellular uptake mechanism, intracellular transportation, and exocytosis of polyamidoamine dendrimers in multidrug-resistant breast cancer cells , 2016, International journal of nanomedicine.

[21]  J. Mendieta-Wejebe,et al.  N-(2-hydroxyphenyl)-2-propylpentanamide, a valproic acid aryl derivative designed in silico with improved anti-proliferative activity in HeLa, rhabdomyosarcoma and breast cancer cells , 2016, Journal of enzyme inhibition and medicinal chemistry.

[22]  Elizabeth E. Hull,et al.  HDAC Inhibitors as Epigenetic Regulators of the Immune System: Impacts on Cancer Therapy and Inflammatory Diseases , 2016, BioMed research international.

[23]  J. Alderete,et al.  Methotrexate Complexation with Native and PEGylated PAMAM-G4: Effect of the PEGylation Degree on the Drug Loading Capacity and Release Kinetics , 2016 .

[24]  Prasad Kancherla,et al.  LC–MS/MS characterization of the forced degradation products of ezetemibe: Development and validation of a stability-indicating UPLC method , 2016 .

[25]  C. DeSouza,et al.  HDAC Inhibitors as Novel Anti-Cancer Therapeutics. , 2015 .

[26]  J. Mendieta-Wejebe,et al.  A simple validated RP-HPLC bioanalytical method for the quantitative determination of a novel valproic acid arylamide derivative in rat hepatic microsomes. , 2015, Biomedical chromatography : BMC.

[27]  S. Çalış,et al.  Cytotoxicity and in vitro characterization studies of synthesized Jeffamine-cored PAMAM dendrimers , 2014, Journal of microencapsulation.

[28]  Tuqiao Zhang,et al.  Degradation of atenolol by UV/peroxymonosulfate: kinetics, effect of operational parameters and mechanism. , 2013, Chemosphere.

[29]  Y. Agrawal,et al.  Development of forced degradation and stability indicating studies of drugs—A review , 2013, Journal of pharmaceutical analysis.

[30]  M. Markowicz,et al.  Evaluation of poly(amidoamine) dendrimers as potential carriers of iminodiacetic derivatives using solubility studies and 2D-NOESY NMR spectroscopy , 2012, Journal of biological physics.

[31]  P. Oliveira,et al.  The contribution of oxidative stress to drug-induced organ toxicity and its detection in vitro and in vivo , 2012, Expert opinion on drug metabolism & toxicology.

[32]  K. Miłowska,et al.  Interaction between PAMAM-NH₂ G4 dendrimer and 5-fluorouracil in aqueous solution. , 2011, International journal of pharmaceutics.

[33]  R. Schneider,et al.  Chatting histone modifications in mammals. , 2010, Briefings in functional genomics.

[34]  K. Mizuno.  Photochemistry of aromatic compounds , 2010, Photochemistry.

[35]  B. Testa,et al.  Qualitative structure-metabolism relationships in the hydrolysis of carbamates , 2010, Drug metabolism reviews.

[36]  Ming Fang,et al.  Effect of Mass Transport in the Synthesis of Partially Acetylated Dendrimer: Implications for Functional Ligand-Nanoparticle Distributions. , 2010, Macromolecules.

[37]  David S. Goodsell,et al.  AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibility , 2009, J. Comput. Chem..

[38]  A. Ornoy.  Valproic acid in pregnancy: how much are we endangering the embryo and fetus? , 2009, Reproductive toxicology.

[39]  J. Hallas,et al.  Cancer Risk in Long-term Users of Valproate: A Population-Based Case-Control Study , 2009, Cancer Epidemiology Biomarkers & Prevention.

[40]  A. Dueñas-González,et al.  Valproic acid as epigenetic cancer drug: preclinical, clinical and transcriptional effects on solid tumors. , 2008, Cancer treatment reviews.

[41]  J. M. Clancy,et al.  Prodrugs for Amines , 2008, Molecules.

[42]  Jerry L. Workman,et al.  Histone acetyltransferase complexes: one size doesn't fit all , 2007, Nature Reviews Molecular Cell Biology.

[43]  Yuming Huang,et al.  Binding study of drug with bovine serum album using a combined technique of microdialysis with flow-injection chemiluminescent detection. , 2004, Journal of pharmaceutical and biomedical analysis.

[44]  T. Baillie,et al.  Role of biotransformation in drug-induced toxicity: influence of intra- and inter-species differences in drug metabolism. , 2011, Drug metabolism and pharmacokinetics.

[45]  M. Phale,et al.  Stress degradation studies and development of a validated stability-indicating-assay-method for determination of diacerein in presence of degradation products , 2011, Pharmaceutical methods.

[46]  Khaled Greish,et al.  Enhanced permeability and retention (EPR) effect for anticancer nanomedicine drug targeting. , 2010, Methods in molecular biology.

[47]  E. Olson,et al.  The many roles of histone deacetylases in development and physiology: implications for disease and therapy , 2009, Nature Reviews Genetics.

[48]  M. Göttlicher.  Valproic acid: an old drug newly discovered as inhibitor of histone deacetylases. , 2004, Annals of hematology.

[49]  T. Chang,et al.  Influence of CYP2C9 genotypes on the formation of a hepatotoxic metabolite of valproic acid in human liver microsomes , 2003, The Pharmacogenomics Journal.

[50]  G Zbinden,et al.  Toxicological screening. , 1984, Regulatory toxicology and pharmacology : RTP.